China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.5
(0.4%)
USD 2.5
(0.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -3.09 Million USD | 47.79% |
| 2023 | -5.93 Million USD | -3.46% |
| 2022 | -5.73 Million USD | -108.72% |
| 2021 | -2.74 Million USD | 73.29% |
| 2020 | -10.28 Million USD | -768.38% |
| 2019 | 1.53 Million USD | 29.61% |
| 2018 | 1.18 Million USD | 0.21% |
| 2017 | 1.18 Million USD | 737.3% |
| 2016 | 141.54 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 3.29 Million USD | 134.02% |
| 2024 Q1 | -4.84 Million USD | -9.19% |
| 2024 Q4 | 3.29 Million USD | 0.0% |
| 2024 FY | -3.09 Million USD | 47.79% |
| 2024 Q2 | -9.69 Million USD | -100.0% |
| 2023 Q2 | -1.49 Million USD | -100.0% |
| 2023 Q4 | -4.44 Million USD | -100.0% |
| 2023 Q3 | -2.22 Million USD | -48.54% |
| 2023 Q1 | -747.3 Thousand USD | -132.18% |
| 2023 FY | -5.93 Million USD | -3.46% |
| 2022 Q1 | -1.54 Million USD | -129.11% |
| 2022 Q4 | 2.32 Million USD | 275.62% |
| 2022 Q2 | -3.09 Million USD | -100.0% |
| 2022 Q3 | -1.32 Million USD | 57.24% |
| 2022 FY | -5.73 Million USD | -108.72% |
| 2021 Q3 | -2.06 Million USD | -398.96% |
| 2021 Q4 | 5.3 Million USD | 357.17% |
| 2021 FY | -2.74 Million USD | 73.29% |
| 2021 Q2 | 690.62 Thousand USD | 0.0% |
| 2021 Q1 | 690.62 Thousand USD | 106.71% |
| 2020 Q2 | -2.34 Million USD | -100.0% |
| 2020 Q3 | -3.96 Million USD | -69.07% |
| 2020 FY | -10.28 Million USD | -768.38% |
| 2020 Q1 | -1.17 Million USD | -176.27% |
| 2020 Q4 | -10.28 Million USD | -159.15% |
| 2019 Q1 | 497.52 Thousand USD | 173.56% |
| 2019 FY | 1.53 Million USD | 29.61% |
| 2019 Q3 | 272.09 Thousand USD | -72.66% |
| 2019 Q2 | 995.05 Thousand USD | 100.0% |
| 2019 Q4 | 1.53 Million USD | 465.7% |
| 2018 FY | 1.18 Million USD | 0.21% |
| 2018 Q3 | 1 Million USD | 155.48% |
| 2018 Q4 | 181.87 Thousand USD | -81.92% |
| 2018 Q1 | 393.65 Thousand USD | 5.03% |
| 2018 Q2 | 393.65 Thousand USD | -0.0% |
| 2017 Q4 | 374.81 Thousand USD | 0.0% |
| 2017 FY | 1.18 Million USD | 737.3% |
| 2016 FY | 141.54 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 106.434% |
| Embecta Corp. | 70.4 Million USD | 104.401% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 116.5% |
| Dynavax Technologies Corporation | -6.38 Million USD | 51.502% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 98.519% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 107.385% |
| PainReform Ltd. | -9.34 Million USD | 66.839% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 60.629% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 31.236% |
| SCYNEXIS, Inc. | 67.04 Million USD | 104.622% |
| Cosmos Health Inc. | -18.54 Million USD | 83.29% |
| Journey Medical Corporation | -3.85 Million USD | 19.581% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 31.236% |
| Safety Shot Inc | -15.08 Million USD | 79.457% |
| Alpha Teknova, Inc. | -36.78 Million USD | 91.575% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 97.782% |
| Bright Green Corporation | -13.12 Million USD | 76.397% |
| Procaps Group, S.A. | 42.54 Million USD | 107.284% |
| Theratechnologies Inc. | -23.95 Million USD | 87.066% |
| Harrow Health, Inc. | -24.41 Million USD | 87.307% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 35.915% |
| Biofrontera Inc. | -20.13 Million USD | 84.608% |
| DURECT Corporation | -27.62 Million USD | 88.783% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 335.451% |
| Cronos Group Inc. | -73.96 Million USD | 95.811% |
| OptiNose, Inc. | -35.48 Million USD | 91.268% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.691% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 92.657% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 112.956% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 162.66% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 2060.687% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 50.655% |
| Radius Health, Inc. | -25.79 Million USD | 87.986% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 49.724% |
| ProPhase Labs, Inc. | -16.78 Million USD | 81.537% |
| Phibro Animal Health Corporation | 2.41 Million USD | 228.25% |
| Procaps Group S.A. | 42.54 Million USD | 107.284% |
| Alvotech | -551.73 Million USD | 99.438% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 69.853% |
| Viatris Inc. | 54.7 Million USD | 105.665% |
| Rockwell Medical, Inc. | -8.43 Million USD | 63.283% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 80.443% |
| SIGA Technologies, Inc. | 68.06 Million USD | 104.552% |
| Tilray Brands, Inc. | -244.98 Million USD | 98.735% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 125.793% |
| Shineco, Inc. | -22.44 Million USD | 86.197% |
| PetIQ, Inc. | 2.13 Million USD | 245.403% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 27.972% |
| Incannex Healthcare Limited | -18.45 Million USD | 83.214% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 101.241% |
| Alimera Sciences, Inc. | -20.13 Million USD | 84.609% |
| Silver Spike Investment Corp. | 7.34 Million USD | 142.214% |
| Assertio Holdings, Inc. | -331.94 Million USD | 99.067% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 53.001% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 62.043% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 82.689% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 84.552% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 98.067% |
| Hempacco Co., Inc. | -13.12 Million USD | 76.394% |
| Talphera, Inc. | -18.39 Million USD | 83.157% |
| Alvotech | -551.73 Million USD | 99.438% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 108.693% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 100.949% |
| Currenc Group, Inc. | -15.3 Million USD | 79.757% |
| Kamada Ltd. | 8.28 Million USD | 137.404% |
| Indivior PLC | 2 Million USD | 254.927% |
| Evoke Pharma, Inc. | -7.79 Million USD | 60.236% |
| Flora Growth Corp. | -57.03 Million USD | 94.567% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 84.552% |
| Evolus, Inc. | -61.68 Million USD | 94.977% |
| HUTCHMED (China) Limited | 100.78 Million USD | 103.075% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 102.253% |
| Akanda Corp. | -32.27 Million USD | 90.4% |